Encouraging data for ViiVs longacting twodrug HIV therapy

Encouraging data for ViiV’s long-acting, two-drug HIV therapy

ViiV Healthcare has unveiled encouraging mid-stage data backing a long-acting formulation of its two-drug regimen cabotegravir and rilpivirine for the treatment of HIV.

Original Article: Encouraging data for ViiV’s long-acting, two-drug HIV therapy

More From BioPortfolio on "Encouraging data for ViiV’s long-acting, two-drug HIV therapy"